NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Beartrap12, based on the company’s own wording, this in vivo booster technology is not positioned as a replacement for DCVax-L or DCVax-Direct. Instead, it’s clearly described as a complementary strategy, particularly for patients who have already completed their vaccine course.

By mobilizing and activating endogenous dendritic cells entirely in vivo, it could potentially extend the immune activation window, help maintain T cell memory, or reinvigorate anti-tumor responses without the need for additional ex vivo manufacturing. Think of it more as a maintenance or follow-up immune strategy — possibly as part of a longer-term treatment plan in combination with the core DCVax platforms.